To the Editor:Hereditary severe insulin resistance syndrome(H-SIRS)shows a wide and variable clinical spectrum and results in severe complications in the endocrinological and cardiovascular systems.Multiple treatments...To the Editor:Hereditary severe insulin resistance syndrome(H-SIRS)shows a wide and variable clinical spectrum and results in severe complications in the endocrinological and cardiovascular systems.Multiple treatments are recommended to control hyperglycemia in H-SIRS,including dietary intervention,insulin therapy,insulin sensitization,and recombinant human insulin-like growth factor-1(rhIGF-1)administration.[1]However,the heterogeneous etiology of H-SIRS leads to poor glycemic control in patients with different mutations,requiring multiple antihyperglycemic medications.This study described two cases diagnosed with H-SIRS and the treatment effect of multi-drug therapy and sodium-glucose cotransporter 2 inhibitor(SGLT2i)monotherapy.展开更多
基金National Natural Science Foundation of China(Nos.8217033609,81770880,and 81970762)Science&Technology Department of Hunan Province(Nos.2020SK2080 and 2015JC3012)Science&Technology Department of Changsha City(Nos.k1906019 and kq190111)
文摘To the Editor:Hereditary severe insulin resistance syndrome(H-SIRS)shows a wide and variable clinical spectrum and results in severe complications in the endocrinological and cardiovascular systems.Multiple treatments are recommended to control hyperglycemia in H-SIRS,including dietary intervention,insulin therapy,insulin sensitization,and recombinant human insulin-like growth factor-1(rhIGF-1)administration.[1]However,the heterogeneous etiology of H-SIRS leads to poor glycemic control in patients with different mutations,requiring multiple antihyperglycemic medications.This study described two cases diagnosed with H-SIRS and the treatment effect of multi-drug therapy and sodium-glucose cotransporter 2 inhibitor(SGLT2i)monotherapy.
